Ewing Sarcoma – Pipeline Review, H2 2017 – Research and Markets

DUBLIN–(BUSINESS WIRE)–The “Ewing
Sarcoma – Pipeline Review, H2 2017”
report has been added to Research
and Markets’
offering.

Ewing Sarcoma – Pipeline Review, H2 2017, provides comprehensive
information on the therapeutics under development for Ewing Sarcoma
(Oncology), complete with analysis by stage of development, drug target,
mechanism of action (MoA), route of administration (RoA) and molecule
type. The guide covers the descriptive pharmacological action of the
therapeutics, its complete research and development history and latest
news and press releases.

The Ewing Sarcoma (Oncology) pipeline guide also reviews of key players
involved in therapeutic development for Ewing Sarcoma and features
dormant and discontinued projects. The guide covers therapeutics under
Development by Companies /Universities /Institutes, the molecules
developed by Companies in Phase III, Phase II, Phase I, Preclinical and
Discovery stages are 1, 13, 6, 20 and 2 respectively. Similarly, the
Universities portfolio in Phase II, Phase I and Preclinical stages
comprises 2, 2 and 2 molecules, respectively.

Ewing Sarcoma (Oncology) pipeline guide helps in identifying and
tracking emerging players in the market and their portfolios, enhances
decision making capabilities and helps to create effective counter
strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Ewing Sarcoma – Overview
  3. Ewing Sarcoma – Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Pipeline by Universities/Institutes
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Ewing Sarcoma – Therapeutics Assessment
  10. Assessment by Target
  11. Assessment by Mechanism of Action
  12. Assessment by Route of Administration
  13. Assessment by Molecule Type
  14. Ewing Sarcoma – Companies Involved in Therapeutics Development
  • Amgen Inc
  • AntiCancer Inc
  • Astellas Pharma Inc
  • Bristol-Myers Squibb Co
  • Cebiotex SL
  • Celgene Corp
  • Celldex Therapeutics Inc
  • Eisai Co Ltd
  • EntreChem SL
  • Exelixis Inc
  • Gradalis Inc
  • Incyte Corp
  • Ipsen SA
  • MacroGenics Inc
  • MediaPharma SRL
  • Merck & Co Inc
  • Merrimack Pharmaceuticals Inc
  • NantKwest Inc
  • Novartis AG
  • Oncomatryx Biopharma SL
  • Oncternal Therapeutics Inc
  • Pfizer Inc
  • Pharma Mar SA
  • Tarveda Therapeutics Inc
  • Tesaro Inc

For more information about this report visit https://www.researchandmarkets.com/research/6cgjg7/ewing_sarcoma?w=4

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Oncology
Drugs